Why Retatrutide May Outperform GLP-1 Drugs

<p>📢 Ask Dr. Bikman’s Digital Mind (multilingual): <a href="https://benbikman.com/ben-bikmans-digital-ai-mind" rel="noopener noreferrer" target="_blank">https://benbikman.com/ben-bikmans-digital-ai-mind</a></p><br /><p>📢 Dr. Bikman’s Community &amp; Coaching Site: <a href="https://insuliniq.com" rel="noopener noreferrer" target="_blank">https://insuliniq.com</a></p><br /><p>Topic:</p><p>Retatrutide activates GLP-1, GIP, and glucagon receptors, combining appetite suppression with increased energy expenditure and powerful liver fat reduction. Dr. Bikman argues that its best use is not as a permanent shortcut, but as a tool to help people regain control over food habits and eventually reduce reliance on medication.</p><br /><p>Summary:</p><p>Dr. Ben Bikman explains retatrutide, a next-generation metabolic drug that activates three receptors at once: GLP-1, GIP, and glucagon. While semaglutide targets GLP-1 and tirzepatide targets GLP-1 plus GIP, retatrutide adds a third arm through glucagon receptor activation. This makes it distinct because GLP-1 and GIP mainly reduce food intake, while glucagon adds an energy-output effect by increasing fat oxidation, liver fat clearance, and energy expenditure.</p><br /><p>Dr. Bikman focuses especially on glucagon because it is the novel feature of retatrutide. In the liver, glucagon stimulates fat burning, suppresses new fat production, promotes hepatic fat clearance, and increases energy expenditure through futile cycling and FGF21 signaling. Human trials show remarkable reductions in body weight and liver fat, with some studies reporting over 80% relative reductions in hepatic fat content and nearly 90% of treated participants reaching normal liver fat levels.</p><br /><p>He also explains that glucagon receptors are not expressed on skeletal muscle, which means the drug’s glucagon arm should not directly signal muscle breakdown. Instead, the liver and fat tissue respond while muscle largely ignores the glucagon signal. The practical takeaway is that retatrutide may represent the next major step in incretin-based therapy, but Dr. Bikman emphasizes again that these drugs should ideally be used as a temporary tool—a crutch—to help people reduce cravings, relearn eating patterns, and ultimately rely less on medication over time.</p><br /><p>References:</p><p>For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&amp;A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: <a href="https://www.benbikman.com" rel="noopener noreferrer" target="_blank">https://www.benbikman.com</a></p><br /><p>NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.</p><hr /><p style="color: grey; font-size: 0.75em;"> Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer" style="color: grey;" target="_blank">acast.com/privacy</a> for more information.</p>